Gotland

Gotland is an early-stage biotechnology company focused on developing a novel class of therapeutics for the treatment of cancer and inflammatory diseases. The company operates primarily in stealth mode, leveraging proprietary insights into cellular signaling pathways to identify and validate new drug targets. Gotland's approach combines advanced computational biology with high-throughput screening to accelerate the discovery of small molecule candidates. While specific pipeline details remain confidential, the company is building a portfolio of programs aimed at addressing significant unmet needs in oncology and immunology.